natgillin/translations-raw huggingface dataset:
Pharmaceutical composition comprising a VLP according to any of the above claims wherein at least 1%, preferably at least 15%, more preferably at least 50%, in particular preferred at least 95% of the total amount of drug substance (cargo) is fully encapsulated in the hull of the VLP. Pharmaceutical composition according to claim 15 wherein the VLPs are non-aggregated. 
Farmaceutski pripravak namijenjen uporabi u postupku liječenja terapijom ili metodom in vivo dijagnosticiranjaze neurološkog poremećaja središnjeg živčanog sustava, pri čemu farmaceutski pripravak sadrži virusu sličnu česticu (VLP) prema bilo kojem od gore navedenih patentnih zahtjeva pri čemu najmanje 1%, poželjno najmanje 15%, još poželjnije najmanje 50%, u osobito poželjno 95% ukupna količina supstance lijeka (teret) je potpuno enkapsulirana u opni virusu slične čestice (VLP) 1 pri čemu je neurološki poremećaj odabran iz skupine koja obuhvaća moždani udar, ovisnost o alkoholu, Alzheimerovu bolest, anksioznost, hiperkineički
The composition for use of claims 1 to 3, for administration selected from the group consisting of intravenously, intramuscularly, intradermally, intraperitoneally, subcutaneously, by spray/aerosol, orally, intraocularly, intratracheally, and intranasally. 
Pripravak namijenjen upotrebi u skladu s patentnim zahtjevima 1 do 3, naznačen time što je namijenjen primjeni koju se bira iz skupine koju čine intravenska, intramuskularna, intradermalna, intraperitonealna, supkutana, spreje/aerosolom, oralna, intraokularna, intratrahealna, te intranazalna.
GAR transformylase converts glycinamide ribonucleotide (GAR) to formylglycinamide ribonucleotide (FGAR) using N10-formyltetrahydrofolate, whereas AICAR transformylase uses the same compound to convert 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) to N-formylaminoimidazole-4-carboxamide ribonucleotide (FAICAR), as shown below. 
GAR transformilaza prevodi glicinamid ribonuklcotide (GAR) u formilglicinamid ribonuklcotide (FGAR) pomoću N'"-formiltetrahidrofolata, dok AICAR transformilaza koristi isti spoj za prevođenje 5-aminoimidazol-4-karboksamid ribonukleotida (AICAR) u N- formilaminoimidazol-4-karboksamid ribonukleotid (FAICAR), kao što je pokazano ispod. Ć
The method of claim 1, wherein the second predictor is selected from the group consisting of: low CD68, PSMB1 (P11A) polymorphism, PSMB5 (R24C) polymorphism, age of under 65, one prior treatment, low Follicular Lymphoma International Prognostic Index (FLIPI) score, and low tumor burden. 
Postupak prema zahtjevu 1, naznačen time da je drugi prediktor izabran iz grupe koju čine: nizak CD68, PSMB1 (PILA) polimorfizam, PSMB5 (R24C) polimorfizam, starost ispod 65, jedno preliminarno liječenje, nizak rezultat Međunarodnog prognostičkog indeksa za folikularne limfome (FLIPI), i nisko tumorsko opterećenje.
means for supplying airflow in said stall for drying and ironing said garments, while the latter are hung up on said hangers or models, wherein said hangers or models (18) for the garments to be treated have different dimensions, thickness and shapes to support garments of various sizes and to keep each garment spread and stretched so that its front parts are separated from the rear parts; characterized in that the system is further provided with one or more rotating spraying nozzle (21), flush with and directing onto the dirtier parts, in particular the neck and/or cuffs of a garment to be washed; in that the system further comprises one or more nozzles for delivering water jets into at least some spread and stretched garments on hangers or models (18); and in that the garment washing is programmable so that to insist on dirty areas with the nozzles, or brushes if present, for all the time necessary to obtain the desired cleanliness. 
- = sredstvo za dovođenje zračne struje u navedenu kabinu, namijenjeno sušenju i glačanju navedene odjeće, gdje je potonja izvješena na navedenim vješalicama ili modelima, gdje navedene vješalice ili modeli (18) za odjeću koju treba obraditi imaju različite dimenzije, debljinu i oblike kako bi mogli nositi odjeću različitih veličina i držati svaki dio odjeće tako raširen i ispružen da su njegovi prednji dijelovi odvojeni od stražnjih dijelova; naznačen time što sustav dodatno ima jednu ili više zakretljivih mlaznica za prskanje (21), u razini i usmjerenih na prljavije dijelove, osobito ovratnik i/ili manžete dijela odjeće koji treba oprati; što sustav dodatno ima jednu ili više mlaznica za dopremanje mlazova vode na u najmanju ruku dio raširene i ispružene odjeće na vješalicama ili modelima (18); te što se pranje dijela odjeće može programirati tako da se prljavim područjima posveti mlaznicama, ili četkama, ako ih ima, svo potrebno vrijeme, kako bi se postiglo željenu čistoću.
A method as claimed in claim 1, characterized in that a filtrate passed through the filter band (122) and containing purified water originating from the aqueous fluid is discharged into the sea or led to the exhaust gas scrubber (1). 
Postupak prema zahtjevu 1, naznačen time da da filtrat prolazi kroz traku za filtriranje (122) i sadrži pročišćenu vodu koja potječe iz vodene tekućine koja se ispušta u more ili dovodi do pročistača ispušnog plina (1).
Number of interferograms 32 
Broj međunarodne objave:
A compound that binds to and activates the erythropoietin receptor (EPO-R), which compound comprises a peptide dimer having the formula: wherein 
HR P20090251 T1 Spoj koji se veže na i aktivira eritropoctinski receptor (EPO-R), gdje navedeni spoj sadrži peptidni dimer formule:
A combination for use according to any one of the preceding claims characterised in that the active ingredients (a) and (b) form part of a single pharmaceutical composition. 
Kombinacija sukladno bilo kojem prethodnom patentnom zahtjevu, naznačena time, da djelatni sastojci (a) i <b) čine jedinstveni farmaceutski pripravak.
The reduction of the double bond may be performed using standard heterogeneous hydrogenation procedures or using homogeneous hydrogenation methods such as e.g. Crabtree's or Wilkinson's catalysts (see e.g. Encyclopedia of Reagents for Organic Synthesis, Paquette (Ed.), Wiley (1995), ISBN 0471936235, p. 
Redukcija dvostruke veze može biti obavljena preko standardnih procedura heterogene hidrogenacije ili preko načina homogene hidrogenacije poput npr. Crabtreejevih ili Wilkinsonovih katalizatora (vidi npr. Encyclopedia of Reagents of Organic Synthesis, Paquette (Ed.), Wiley (1995.), ISBN 0471936235, str.
An image processing apparatus for processing an image obtained by fluoroscopying a subject, the image processing apparatus includes: a band-image generating device configured to generate a band image by extracting a part of frequency components in an original image with a figure of the subject appearing therein; 
(A) uređaj za stvaranje slike na traci (12) koji ima konfiguraciju za stvaranje slike na traci pomoću ekstrakcije dijela frekvencijskih komponenti u originalnoj slici (PO) s likom pojedinca koji se pojavljuje na toj slici;
The activation of bradykinin B1 and B2 receptors induces relaxation of vasal muscles with consequent hypotension, increase in vascular permeability, contraction of smooth muscles of intestine and respiratory tract, stimulation of nociceptive neurons, alteration of ionic epithelial secretion, production of nitroxide and release of cytokines by leukocytes and eicosanoids from different cell types. 
Aktivacija B1 i B2 receptora bradikinina inducira relaksaciju vazalnih mišića čega je posljedica hipotenzija, povećanje vaskularne permeabilnosti, kontrakcija glatkih mišića probavnog i respiratornog trakta, stimulacija neurona za osjet boli. mijenjanje ionskog epitelnog izlučivanja, produkcija nitroksida 1 oslobađanje citokina od leukocita 1 eikosanoida iz različitih tipova stanica.
the colder fluid thereafter continues to flow through the array of valves or the seal skirt (30) towards the non-insulated areas of the inner rotor (IR) where his temperature raises due to the environmental thermal energy. 
- - hladniji fluid dalje nastavlja strujiti kroz niz ventila ili brtvila (30) prema neizoliranoj zoni unutarnjeg rotora (IR), gdje temperatura fluida počinje ponovno Tasti kao posljedica razmjene topline sa toplijom ambijentalnom sredinom.
The method of clause 5, wherein the at least one secondary anti-retroviral or other adjunctive therapeutic agent is selected from the group consisting of: protease inhibitors, nucleoside reverse transcriptase, non-nucleoside reverse transcriptase inhibitors, combination drugs, entry and fusion inhibitors, acyclovir, adefovir dipivoxil, aldesleukin, amphotericin b, azithromycin, calcium hydroxylapatite, clarithromycin, doxorubicin, dronabinol, entecavir, epoetin alfa, etoposide, fluconazole, ganciclovir, immunoglobulins, interferon alfa-2, isoniazid, itraconazole, megestrol, paclitaxel, peginterferon alfa-2, pentamidine, poly-l-lactic acid, ribavirin, rifabutin, rifampin, somatropin, testosterone, trimetrexate, valganciclovir; integrase inhibitors, microbicides, and IL-2. 
Uporaba prema zahtjevu 3, gdje se barem jedno dodatno anti-retrovirusno ili drugo dopunsko terapijsko sredstvo odabire iz skupine koju čine: inhibitori proteaze, nukleozidni inhibitori reverzne transkriptaze, ne-nukleozidni inhibitori reverzne transkriptaze, kombinirani lijekovi, inhibitori ulaza i fuzije, aciklovir, adefovir dipivoksil, aldesleukin, amfotericin b, azitromicin, kalcijev hidroksilapatit, klaritromicin, doksorubicin, dronabinol, entekavir, epotein alfa, etopozid, flukonazol, ganciklovir, imunoglobulini, interferon alfa-2, izoniazid, ribavirin, rifabutin, rifampin, somatropin, testosteron, trimetreksat, valganciklovir; inhibitori integraze, mikrobicidi, i IL-2.
A compound represented by the following Formula (I): wherein: 
PATENTNI ZAHTJEVI Sastav predstavljen slijedećom Formulom (1): pri čemu:
The process of clause 1, wherein at least a portion of the process occurs in equipment comprising a reaction zone, a separation zone, and a condensing zone. The process of clause 5, wherein the separation zone comprises a distillation component. 
Postupak prema zahtjevu 1, gdje se barem dio postupka pripreme 1,1,1,2,3-pentakloropropana odvija u opremi koja obuhvaća reakcijsku zonu, zonu odvajanja koja po izboru ima destilacijsku komponentu, i zonu kondenzacije.
Provided herein is a process for making compounds of formula I: 
PATENTNI ZAHTJEVI 1. = Postupak dobivanja spoja formule I:
The use of at least one stabilizer selected from epoxidized animal oil; epoxidized vegetable oil; a nonionic or anionic polyoxyethylene surfactant; a polyhydric alcohol; hydroxides, carbonates and bicarbonates of alkali metals; hydroxides, carbonates and bicarbonates of alkaline earth metals; aqueous silicate solutions; basic silicates; and alkaline earth metal basic silicate, for controlling degradation of Cyazofamid. 
Uporaba, naznačena time, da je najmanje jedan stabilizator odabran od sljedećih: epoksidirano životinjsko ulje; epoksidirano biljno ulje; neionski ili anionski tenzid polioksietilena; polihidrični alkohol; hidroksidi, karbonati i bikarbonati od alkalijskih metala; hidroksidi, karbonati i bikarbonati od zemnoalkalijskih metala; vodene silikatne otopine; bazični silikati; i bazični silikati zemnoalkalijskih metala, koji se koristi za sprečavanje propadanja cijazofamida.
When tensioning is effected, the container 13 is moved axially downwards until the container 13 assumes a final position in the tensioned state, as indicated in FIG. 5 . 
Kad je postignuto naprezanje, spremnik se pomakne aksijalno prema dolje sve dok spremnik 13 zauzme svoj krajnji položaj u napregnutom stanju, kako je prikazano na slici 5.
wherein a periodicity of the sequence of synchronization spread sequences is equal to a number of bits of a binary message, or wherein a periodicity of the sequence of synchronization spread sequences is shorter than the number of bits of the binary message. 
Generator vodenog žiga prema zahtjevu 2 ili zahtjevu 3, naznačen time, da je uređaj za umetanje sinhronizacije konfiguriran za višestruko kombiniranje prikaza proširene informacije s periodičnim nizom (S) od nizova proširene sinhronizacije (a, b, c, a, b, c);1 gdje je periodičnost niza od nizova proširene sinhronizacije jednaka broju bitova u binarnoj poruci, ili pri čemu je periodičnost niza od nizova proširene smhronizacije kraća od broja bitova u binarnoj poruci.
The method according to Claim 20, wherein the antigen is loaded onto class I MHC molecules expressed on the surface of a suitable antigen-presenting cell by contacting a sufficient amount of the antigen with an antigen-presenting cell. 
Metoda sukladno Tvrdnji 20, pri čemu se antigen nalazi na molekulama MHC klase I koje su izražene na površini prikladne stanice koja predstavlja antigen kontaktiranjem dovoljne količine antigena sa stanicom koja predstavlja antigen.
The shelf according to claim 1, wherein the material of the strip has a yield strength of at least 500 MPa. The shelf according to claim 15, wherein the material of the strip has a yield strength of at least 600 MPa. 
Polica (10) sukladno bilo kojem od prethodnih patentnih zahtjeva, pri čemu materijal te trake (21) ima granicu elastičnosti od najmanje 500 MPa, poželjno najmanje 600 MPa.
The process of claim 3, wherein said carboxylic acid is selected from the group consisting of aliphatic and aromatic carboxylic acids. 
Postupak u skladu s patentnim zahtjevom 14, naznačen time što navedenu karboksilnu kiselinu se bira iz skupine koju čine alifatske i aromatske karboksilne kiseline.
Chelating agents are substances used to chelate or bind metallic ions, such as with a heterocylic ring structure so that the ion is held by chemical bonds from each of the participating rings. 
Sredstva za keliranje su tvari koje se upotrebljavaju za keliranje ili vezivanje metalnih iona, kao npr. s heterocikličkom prstenastom strukturom, tako da se ion drži kemijskim vezama za svaki od uključenih prstenova.
The use according to claim 1 for the prevention and/or treatment of polycystic ovary syndrome. 
Uporaba prema zahtjevu 1, za prevenciju i/ili liječenje sindroma policističnih jajnika.
(a-ii) the reaction of a compound of the formula (7): 
(a-11) reakciju spoja formule (7): oN PG-O T
with the proviso that when R, R' and R" are hydrogen and q is zero, and Ra is either -COOH (p is zero) or -WR8 (p is one) and W is oxygen and R8 is hydrogen then at least one of the following occurs: 
pod uvjetom da kada R1, R3, R4, i R5 su vodik, tada R2 nije bromo; i uz dodatni uvjet da kada R, R' i R" su vodik i q je nula, i Ra je bilo -COOH (p je nula) ili -WR8 (p je jedan) i W je kisik i R8 je vodik tada se događa najmanje jedno od slijedećeg:
The extended release dosage form of claim 78, wherein the extended release formulation comprises an opioid analgesic and the immediate release formulation comprises a non opioid analgesic. 
Oblik za doziranje s produljenim otpuštanjem prema zahtjevu 25, naznačen time da formulacija s produljenim otpuštanjem sadrži opioidni analgetik, i formulacija s trenutnim otpuštanjem sadrži neopioidni analgetik.
A combination according to any of the preceding claims wherein R5 and R6 together form a morpholine-4-yl group. 
Sastav prema bilo kojem od prethodnih zahtjeva naznačen time da Rs i Rs zajedno stvaraju morfolin-4-il skupinu.
For example, if the sealing material has a thickness of 0.5 to 2 mm, the maximum allowed gap (in the direction of thickness of the sealing material) can range respectively from about 0.25 to 1 mm. 
Na primjer, ako materijal za brtvljenje ima debljinu 0.5 do 2 mm, maksimalna dopuštena pukotina (u smjeru debljine materijala za brtvljenje) može iznositi od oko 0.25 do 11mm.
Background of the Invention: 
(54) Naziv izuma:
The process of claim 1, wherein the crude 1,1,1,2,3-pentachloropropane is transformed into 1,1,2,3-tetrachloropropene in step (ii) by reactive distillation, wherein the reactive distillation occurs in equipment comprising a reaction zone, a separation zone, and a condensing zone. The process of claim 1, wherein the 1,1,2,3-tetrachloropropene and hydrogen chloride are removed from the reaction zone via the separation zone and the condensing zone, whereby at least some of the 1,1,2,3-tetrachloropropene is separated as a liquid condensate from the hydrogen chloride vapor, producing purified hydrogen chloride vapor, and a crude 1,1,2,3-tetrachloropropene. 
Postupak prema zahtjevu 11, gdje se sirovi 1,1,1,2,3-pentakloropropan pretvara u 1,1,2,3-tetrakloropropen reaktivnom destilacijom, gdje se reaktivna destilacija odvija u opremi koja obuhvaća reakcijsku zonu, zonu odvajanja i zonu kondenzacije, gdje se 1,1,2,3-tetrakloropropen i klorovodik uklanjanju iz reakcijske zone putem zone odvajanja i zone kondenzacije, pri čemu se barem dio 1,1,2,3-tetrakloropropena odvaja kao tekući kondenzat iz pare klorovodika, čime nastaje pročišćena klorovodična para 1 sirovi 1,1,2,3-tetrakloropropen.
Herbicidal compositions comprising pyroxasulfone VII The present invention relates to herbicidally active compositions, which comprise 3-[5-(difluoromethoxy)-1-methyl-3-(trifluoromethyl)pyrazol-4-ylmethylsulfonyl]-4,5-dihydro-5,5-dimethyl-1,2-oxazole [common name pyroxasulfone] and at least one herbicide B and at least one herbicide B which is selected from group consisting of synthetic auxins and auxin transport inhibitors. 
Herbicidna kompozicija koja sadrži: a) herbicid A koji je 3-[5-(difluorometoksi)-1-metil-3-(trifluorometil)pirazol-4-ilmetilsulfonil]-4,5-dihidro-5,5-dimetil-1,2-oksazol; i b) herbicid B koji je izabran iz grupe koju čine dikamba, njegove soli i njegovi esteri; pri čemu herbicidna kompozicija pored herbicida A 1 herbicida B ne sadrži dodatni herbicid D, koji se razlikuje od herbicida A i herbicida B.
condensing said pyrolysis products from said gas mixture in a condensation chamber, obtaining a condensate liquid phase comprising a product of pyrolysis that is separated from the uncondensed gas, such that said organic liquid can be recycled to a production process of fiberglass-reinforced plastics as a mixture with commercial unsaturated resins; and extracting said solid residue from said pyrolysis chamber. 
kondenziranje (151) navedenih produkta pirolize iz navedene smjese plinova (30) u komori za kondenzaciju uz dobivanje tekuće faze kondenzata (33), koje uključuje glavnu količinu produkta pirolize, koja se odvaja od nekondenziranog plina na način da se navedena organska tekućina (33) može reciklirati iz staklenim vlaknama ojačane plastike u smjesu s komercijalnom nezasićenom poliesterskom smolom;
vii)—A solution of the product obtained in the previous step (1.02 g) in acetone (50 ml) was treated with hydrochloric acid (6 M, 5 ml). 
- Otopinu produkta dobivenog u prethodnom koraku (1,02 g) u acetonu (50 ml) obradi se klorovodičnom kiselinom (6 M, 5 ml).
A method of treating a cancer which is thyroid cancer, ovarian cancer, melanoma, AML or colorectal cancer in a patient comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof. 
Spoj ili sol namijenjeni upotrebi u skladu s patentnim zahtjevom 9, naznačeni time što se rak bira iz skupine koju čine rak štitnjače, rak jajnika, melanom, akuta mijelogena leukemija (AML) i kolorektalni rak.
The present invention relates to compounds of formula (I): 
HR P20180202 T1 PATENTNI ZAHTJEVI m Spoj formule (I):
The compound according to any one of claims 1 to 3, wherein the pain is due to cancer, to a nerve injury or to rheumatic diseases. 
Spoj prema patentnom zahtjevu 1 ili 2, za bol kao posljedicu karcinoma, ozljede živca ili reumatskih bolesti.
The method of item 12, wherein the pluripotent stem cell is a human ESC (hESC) or a human iPSC (hiPSC). 
Postupak sukladno patentnom zahtjevu 6, pri čemu je pluripotentna matična stanica humana embrionalna matična stanica (hESC) ili humana inducirana pluripotentna matična stanica (hiPSC).
Preparation of the composition of the invention 
Broj objave europskog patenta:
In a more preferable embodiment, Ring C is a phenyl group substituted by 1-3 substituents selected from the group consisting of a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group, and a mono- or di-lower alkylamino group; or a heterocyclyl group substituted by a substituent selected from the group consisting of a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, and a halo-lower alkoxy group. 
Y je -CH>»-. Spoj u skladu s patentnim zahtjevom 3, ili njegova farmaceutski prihvatljiva sol, gdje R* je fenilna skupina, supstituirana s atomom halogena, cijano skupinom, C;.4 alkilnom skupinom, halogen-C;.4 alkilnom skupinom, Ci.4 alkoksi skupinom ili halogen-C;.4 alkoksi skupinom; ili heterociklilna skupina, supstituirana s atomom halogena, cijano skupinom, C;.4 alkilnom skupinom ili C;.4 alkoksi skupinom.
Netupitant or a pharmaceutically acceptable salt thereof, for use in treating chemotherapy induced nausea and vomiting ("CINV") induced by highly emetogenic chemotherapy, for a period of five consecutive days in a patient in need thereof, wherein said netupitant is administered in a therapeutically effective amount which is effective to treat nausea and vomiting during the acute and delayed phases of emesis, enters the systemic circulation, crosses the blood brain barrier and occupies at least 70% of NK1 receptors in the striatum seventy-two hours after said administration. 
navedeni netupitant ili njegova farmaceutski prihvatljiva sol je primjenjena na navedenog pacijenta na dan jedan, u terapeutski efikasnoj količini koja je efikasna za liječenje mučnine i povraćanja u toku akutnih i odloženih faza emezisa, i koja ulazi u sustavnu cirkulaciju, prelazi krvno moždanu barijeru i zauzima najmanje 70% NK1 receptora u strijatu sedamdeset i dva sata poslije navedene primjene;
The compound of clause 1, wherein R1 is H or CH3; R2 is H or CH3; R3 is H; and one of R4 and R5 is H, and the other is -CH2-X, wherein X is phenyl or heteroaryl including from 5 to 6 ring atoms wherein 1, 2, or 3 of the ring atoms are independently selected from the group consisting of N, NH, N(C1-C3 alkyl), O, and S; each optionally substituted with from 1-3 substituents independently selected from the group consisting of halogen, cyano, C1-C6 alkyl, hydroxyl, C1-C6 alkoxy, and -N(R')R'. 
Ri je H ili CHs; R> je H ili CH3; Rs je H; i jedan od Ry i Rs je H, i drugi je -CH>-X, pri čemu X je fenil ili heteroaril uključujući od 5 do 6 atoma prstena pri čemu su 1, 2, ili 3 od atoma prstena neovisno odabrani od skupine koja se sastoji od N, NH, N(C;-C: alkila), O 1 S; pri čemu je svaki fenil ili heteroaril izborno supstituiran s od 1-3 supstituenata neovisno odabranih od skupine koja se sastoji od halogena, cijano, C;- Ce alkila, hidroksila, Cy-Cg alkoksi i -N(R')R';
The gas diffusion electrode according to claim 5, wherein the gas diffusion electrode is used in a membrane electrode assembly. 
Primjena plinske difuzijske elektrode u skladu s zahtjevom 5 u sklopu membranske elektrode.
The method of any preceding claim, comprising: (ii) microfluidization of the first emulsion to form a second emulsion having a second average oil droplet size which is less than the first average oil droplet size. 
Postupak prema bilo kojem od prethodnih zahtjeva koji sadrži: (1i) mikrofluidizaciju prve emulzije da bi se formirala druga emulzija koja ima drugu prosječnu veličinu kapljica ulja koja je manja od prve prosječne veličine kapljica ulja.
A solid oral extended release pharmaceutical dosage form obtainable by a process according to any one of claims 57 and 58 . 
Farmaceutski oblik davanja s produljenim otpuštanjem u krutom obliku koji se može dobiti postupkom prema bilo kojem zahtjevu od 1 do 58.